Evidence map›Paper›PMID 33288735›Full record

ArticleAging2020

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.

Yizhen Liu, Juan J Gu, Ling Yang, Ping-Chiao Tsai, Ye Guo, Kai Xue, Zuguang Xia, Xiaojian Liu, Fangfang Lv, Junning Cao and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Obesity and Risk for Lymphoma: Possible Role of Leptin.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Yizhen LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Juan J GuDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Ling YangDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ping-Chiao TsaiDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Ye GuoDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Kai XueDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zuguang XiaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaojian LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Fangfang LvDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Junning CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaonan HongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cory MavisDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Francisco J Hernandez-IlizaliturriDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Qunling ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Fudan University Shanghai Cancer Center · CNRoswell Park Comprehensive Cancer Center · USFudan University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intercellular adhesion molecule-1 (ICAM-1) is a cell-surface receptor contributing to lymphocyte homing, adhesion and activation. The prognostic significance of the protein is unknown in diffuse large B-cell lymphoma (DLBCL) in post-rituximab era. We detected expression of ICAM-1 immunohistochemically in 102 DLBCL tissue samples. Overexpression of ICAM-1 was found in 28 (27.5%) cases. In patients with low ICAM-1 expression levels, the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy resulted in an improved overall response rate, progression-free survival (PFS) and overall survival (OS) (

Indexed as

Antineoplastic Agents, ImmunologicalRituximabAdultAgedAntibody-Dependent Cell CytotoxicityAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleHumansIntercellular Adhesion Molecule-1Lymphoma, Large B-Cell, DiffuseMaleMiddle AgedAntineoplastic Agents, ImmunologicalCyclophosphamideDoxorubicinICAM1 protein, humanIntercellular Adhesion Molecule-1PrednisoneR-CHOP protocolRituximabVincristinechemotherapydiffuse large B-cell lymphomaintercellular adhesion molecule-1prognosisrituximab

Identifiers

PMID33288735
PMCPMC7834997
OpenAlexW3107564903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.